Johnson & Johnson is one of the most stable businesses in the world. The company has increased its adjusted earnings-per-share for 32 consecutive years.
The company has been able to achieve sustained success through diversification within the health care industry and geographical diversification. Johnson & Johnson currently generates more revenue outside the United States than inside.
The company operates in 3 large market-leading segments:
The image below shows the consistent sustained success of Johnson & Johnson:
The key brands in the company’s consumer segment are: Motrin, Tylenol, Benadryl, Zyrtec, Band-Aid, Listerine, Aveeno, Neutrogena, and Johnson’s.
It is highly likely that Johnson & Johnson will continue to deliver dividend increases year-in-and-year-out as the health care industry continues to grow.
|Johnson & Johnson (JNJ)|
|52 Week High||126.07|
|52 Week Low||94.28|
|Analyst Price Targets – Average (15)||125.16|
|10 Year Dividend Growth Rate||8.0% per year|
|Consecutive Dividend Increases||54 years|
|Per share data:|
|Book Value per share (MRQ)||26.70|
|Cash per share (MRQ)||14.85|
|Dividends per share(TTM)
|Dividend Yield (TTM)||2.7%|
|Price to Sales (TTM)||4.41|
|Price to Book Value (MRQ)||4.3|
|Long Term Debt/Equity (MRQ)||32.36|
|Total Debt/Equity (MRQ)
|Earnings Before Taxes (TTM)||19.237M|
|Gross Margin % (TTM)||69.6%|
|Net Profit Margin % (TTM)||22%|
|Revenue Change % (TTM)||2.2%|
|Revenue Change % (MRQ)-1 Year Ago||4.2%|
|TTM:Trailing Twelve Months|
|MRQ:Most Recent Quarter|
|Τμήμα Διεθνών Αγορών|
*Τα όσα αναγράφονται στη στήλη είναι προιόν δημοσιογραφικής έρευνας και δεν αποτελούν προτροπή αγοράς, πώλησης ή διακράτησης μετοχών